Nov 4, 2025
Summary:
According to an article by Sy Boles of the Harvard Gazette, Heavy Menstrual Bleeding (HMB) affects many women, but research progress has been slow due to the lack of suitable animal models. Scientists Donald Ingber, founding director of the Wyss Institute, and Judah Folkman, professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children's Hospital, are developing an innovative "organ-on-a-chip" technology. This breakthrough has enabled the creation of a human model replicating the uterine wall. By providing a more accurate research platform, their work aims to dramatically accelerate the path from symptom onset to effective treatment. While the current average time from initial symptoms to proper diagnosis and care is around five years, the scientists' organ chip model of the human uterus could potentially reduce that period to a mere five months. If successful, this technology promises to transform the medical landscape and provide faster relief for the millions of women suffering from Heavy Menstrual Bleeding.
Article Citation:
Boles, S. (2025, October 7). HMB is more common than asthma
or diabetes, yet often ignored. Harvard
Gazette. https://news.harvard.edu/
Artificial organs that utilize chip-based
technology are not currently available as implantable, fully
functional organ replacements in clinical practice.
Instead, the field is dominated by "organ-on-a-chip" (OOC) or
"organs-on-chips" microfluidic devices, which are advanced in vitro
models that recapitulate key aspects of human organ physiology and
pathophysiology using living human cells within engineered
microenvironments on a chip platform.[1][2][3][4][5]
These systems are primarily used for research applications,
including disease modeling, drug development, toxicity testing, and
personalized medicine. OOC devices have been developed for a
variety of organs—such as lung, liver, heart, kidney, and brain—and
can be integrated into multi-organ platforms ("body-on-a-chip") to
study inter-organ interactions and systemic drug effects.[2][3][4][5] Integration of
biosensors for real-time monitoring and the use of human induced
pluripotent stem cells are advancing the field toward more
physiologically relevant and personalized models.[6][5]
Despite rapid technological progress, significant challenges remain
before chip-based artificial organs can be used as implantable
therapeutic devices. These include issues of vascularization,
immune compatibility, long-term viability, and regulatory approval
for clinical use.[3][4][7][5] Current
regulatory discussions, including those involving the FDA, focus on
the use of OOC systems as preclinical testing platforms rather than
as direct organ replacements.[5]
In summary, chip-based artificial organs are currently
limited to sophisticated in vitro models for research and drug
development, not as implantable devices for organ replacement in
patients.[1][2][3][4][5]
j